Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
World Health Organization (Who)
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Feb 14, 2025
Politics, Policy & Law
FDA thaws communications but sends mixed message on ‘gender ideology’
Agency has resumed release of routine regulatory announcements and complied with a court order to restore some webpages
BioCentury | Jan 22, 2025
Politics, Policy & Law
Trump wipes away some Biden healthcare policies
Hiring and regulatory freeze are standard for White House transitions
BioCentury | Dec 13, 2023
Finance
Dec. 12 Quick Takes: Targeted genomic DNA insertion company Tome launches with $213M
Plus: Bicara’s latest big round is a $165M series C, Shinobi launches, Pfizer readies to close Seagen deal and more
BioCentury | Aug 2, 2023
Product Development
INTREPID’s new strategy to help build a pandemic war chest
The INTREPID Alliance has abandoned its fundraising plans, but not its mission to expedite antiviral development for future pandemics
BioCentury | Apr 6, 2023
Discovery & Translation
Targeted DNA integration; plus Janssen’s small molecule dengue inhibitor and more
BioCentury’s roundup of translational news
BioCentury | Jan 10, 2023
Deals
BioNTech buys AI partner InstaDeep, with which it detected high-risk COVID-19 variants
German biotech pays £362 million up front for balance of machine learning company; had already invested in its series B
BioCentury | Sep 14, 2022
Finance
Sept. 13 Quick Takes: Acelyrin heads for Phase III with $300M round
Plus note deals for Alnylam, Sarepta and updates from Rubius, Relay, Forge, Owkin, Ori and more
BioCentury | Aug 12, 2022
Politics, Policy & Law
Maloney calls on HHS to reduce barriers to monkeypox therapy
Lawmaker contrasts hurdles to access in the U.S. amid push for RCTs for Tpoxx
BioCentury | Jun 15, 2022
Market Access
June 14 Quick Takes: ICER weighs in on Amylyx’s ALS treatment
Plus EQRx’s first regulatory submission, WHO to discuss monkeypox status and updates from PureTech, Tilt and more
BioCentury | May 31, 2022
Product Development
WHO mobilizing monkeypox research strategy
Meeting to discuss designs for trials of therapies, vaccines
Items per page:
1 - 10 of 546